Difference between revisions of "Citalopram-dosulepine"

From Psychiatrienet
Jump to: navigation, search
Line 1: Line 1:
{{Drug
+
{{Drugswitch
 
| from = citalopram
 
| from = citalopram
 
| to = dosulepine
 
| to = dosulepine

Revision as of 18:47, 4 May 2009

Citalopram
Type Antidepressant
Group SSRI
links
ATC-code N06AB04
Medscape Citalopram
PubChem 2771
PubMed Citalopram
Kompas (Dutch) citalopram
Wikipedia citalopram
dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin

Switch medication from citalopram to dosulepine.[1] [2]

Nietinrijdenbord.png Stop citalopram
  • Day 0: gradually reduce dosage of citalopram/escitalopram to a maximum of 20 mg/ day resp. 10 mg/day, when this dosage is respectively > 20 mg/day and > 10 mg/day.
  • Day 1: reduce dosage of citalopram/escitalopram to a maximum of 10 mg/ day resp. 5 mg/day.
Eenrichtingbord.png Start dosulepine
  • Day 1: simultaneously start administration of dosulepine in a normal dosage of 50-75 mg/day.
  • Day 8: stop administration of citalopram/escitalopram and continue administration of dosulepine only.
Infobord.png More information
  • “Start low, go slow” for dosulepine is not required, but caution is necessary.
  • The same applies to escitalopram.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.